<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709355</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-VM1500-08</org_study_id>
    <nct_id>NCT03709355</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs</brief_title>
  <official_title>Open-Label Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of ELPIDA® in Co-Administration With Other Drugs in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viriom</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viriom</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study assesses PK and safety of other drugs, such as some antibiotics, proton pump&#xD;
      inhibitors, statins, and combined oral contraceptives when co-administered with Elpida®&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates the drug-drug interaction of Elpida® and other drugs (Rifampin,&#xD;
      Rifabutin, Clarithromycin, Omeprazole, Atorvastatin and combinations of Levonorgestrel and&#xD;
      Ethinylestradiol) according to changes in the PK parameters of the study substances in their&#xD;
      single co-administration in healthy subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of elsulfavirine</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of VM1500A</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of rifampicin</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of rifabutin</measure>
    <time_frame>49 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of clarithromycin</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of atorvastatin</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of levonorgestrel</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of ethinylestradiol</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of AEs and SAEs</measure>
    <time_frame>49 days</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Elpida®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of Elpida® (capsule 20 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifampin &amp; Elpida®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Rifampin (capsule 150 mg), Rifampin + Elpida® 20mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifabutin &amp; Elpida®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Rifabutin capsule 150 mg, Rifabutin + Elpida® 20mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clarithromycin &amp; Elpida®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Clarithromycin capsule 250 mg, Clarithromycin + Elpida® 20mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omeprazole &amp; Elpida®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Omeprazole capsule 20 mg, Omeprazole + Elpida® 20mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin &amp; Elpida®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Atorvastatin tablet 80 mg, Atorvastatin + Elpida® 20mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levonorgestrel+Ethinylestradiol &amp; Elpida®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Levonorgestrel 150 µg + Ethinylestradiol 150 µg tablet, Levonorgestrel + Ethinylestradiol + Elpida® 20mg single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elpida®</intervention_name>
    <description>Elpida® capsules, 20mg</description>
    <arm_group_label>Atorvastatin &amp; Elpida®</arm_group_label>
    <arm_group_label>Clarithromycin &amp; Elpida®</arm_group_label>
    <arm_group_label>Elpida®</arm_group_label>
    <arm_group_label>Levonorgestrel+Ethinylestradiol &amp; Elpida®</arm_group_label>
    <arm_group_label>Omeprazole &amp; Elpida®</arm_group_label>
    <arm_group_label>Rifabutin &amp; Elpida®</arm_group_label>
    <arm_group_label>Rifampin &amp; Elpida®</arm_group_label>
    <other_name>elsulfavirine</other_name>
    <other_name>VM1500</other_name>
    <other_name>VM-1500</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Rifampin capsules, 150mg</description>
    <arm_group_label>Rifampin &amp; Elpida®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
    <description>Rifabutin capsules, 150mg</description>
    <arm_group_label>Rifabutin &amp; Elpida®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Clarithromycin Film-coated tablets, 250mg</description>
    <arm_group_label>Clarithromycin &amp; Elpida®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Omeprazole Film-coated tablets 20mg</description>
    <arm_group_label>Omeprazole &amp; Elpida®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin Film-coated tablets, 80mg</description>
    <arm_group_label>Atorvastatin &amp; Elpida®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel+Ethinylestradiol</intervention_name>
    <description>Levonorgestrel 150 μg + Ethinylestradiol 30 μg, Film-coated tablets</description>
    <arm_group_label>Levonorgestrel+Ethinylestradiol &amp; Elpida®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy subjects must meet the following criteria to be enrolled in the study:&#xD;
&#xD;
          1. Non-smoking men and women between the ages of 18 and 45 years (inclusive) (only women&#xD;
             in Group 7);&#xD;
&#xD;
          2. Verified &quot;healthy&quot; diagnosis according to standard clinical, laboratory and&#xD;
             instrumental examination methods;&#xD;
&#xD;
          3. Body Mass Index ranges between 18.5 kg/m2 and 30.0 kg/m2 and a body weight NLT 50 kg;&#xD;
&#xD;
          4. Negative alcohol and drug tests;&#xD;
&#xD;
          5. Consent to use two adequate and reliable methods of contraception throughout the study&#xD;
             and up to 3 months after its completion: a condom with spermicide (foam, gel, cream,&#xD;
             suppositories), or a diaphragm with spermicide, or a condom and diaphragm, or a condom&#xD;
             and an intrauterine device;&#xD;
&#xD;
          6. Signed Patient Information Sheet and form of Informed Consent to participate in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A subject will be considered not eligible to participate in the study if one or more of the&#xD;
        following criteria is met:&#xD;
&#xD;
          1. Chronic diseases of cardiovascular, bronchopulmonary, neuroendocrine, musculoskeletal&#xD;
             system, as well as diseases of the gastrointestinal tract, liver, kidneys, blood;&#xD;
&#xD;
          2. Variables of standard laboratory and instrumental parameters are beyond the normal&#xD;
             limits (taking into account the acceptable limits of laboratory parameters;&#xD;
&#xD;
          3. Surgical interventions on the gastrointestinal tract in medical history (except&#xD;
             appendectomy);&#xD;
&#xD;
          4. Systolic pressure below 90 mm Mercury or above 130 mm Mercury, diastolic pressure&#xD;
             below 60 mm Mercury or above 85 mm Mercury, heart rate less than 60 BPM or more than&#xD;
             90 BPM at screening;&#xD;
&#xD;
          5. Regular intake of drugs less than 2 weeks prior to screening (including herbal&#xD;
             preparations and dietary supplements); intake of drugs that have a pronounced effect&#xD;
             on hemodynamics, hepatic function, etc. (for example, barbiturates, omeprazole,&#xD;
             cimetidine, etc.) less than 30 days prior to screening;&#xD;
&#xD;
          6. Presence of antibodies to HIV and hepatitis C virus, presence of hepatitis В surface&#xD;
             antigen, a positive syphilis test;&#xD;
&#xD;
          7. An unstable sleep structure (e.g., night work, sleep disorders, insomnia, recent&#xD;
             return from another time zone, etc.), extreme physical activity (e.g. weight lifting),&#xD;
             a special diet (e.g. vegetarian, vegan);&#xD;
&#xD;
          8. Signs of alcohol (intake of more than 10 units of alcohol per week) or drug addiction;&#xD;
             alcohol or drugs consumption within 4 days prior to screening; cigarettes smoking 3&#xD;
             months prior to screening; positive drug and/or alcohol test;&#xD;
&#xD;
          9. Drug allergies in medical history (including drug intolerance, including&#xD;
             hypersensitivity to any components of study drugs) as well as food allergy;&#xD;
&#xD;
         10. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption;&#xD;
&#xD;
         11. Individual intolerance to any components of study drugs;&#xD;
&#xD;
         12. Blood/plasma donation (450 ml of blood or plasma and more) less than 2 months prior to&#xD;
             screening;&#xD;
&#xD;
         13. Treatment with a study drug in framework of other clinical trials within 1 month prior&#xD;
             to screening (including follow-up visits);&#xD;
&#xD;
         14. Acute infectious diseases less than 4 weeks prior to screening;&#xD;
&#xD;
         15. Inhibitors or inducers of CYP3A4/5, drugs that cause QT prolongation within 30 days&#xD;
             prior to StD administration;&#xD;
&#xD;
         16. For women - positive result of pregnancy test or breastfeeding; Inability to read or&#xD;
             write; unwillingness to understand and adhere to the study protocol procedures;&#xD;
             non-compliance with the drugs intake regimen or execution of procedures, which as the&#xD;
             Investigator believes may affect the study results or subject's safety and prevent the&#xD;
             subject from further participation in the study; any other associated medical or&#xD;
             serious psychological conditions making the subject not eligible to participate in the&#xD;
             clinical study, restricting legality of obtaining the Informed Consent or affecting&#xD;
             the subject's ability to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Smolyarchuk, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>I.M. Sechenov First Medical State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alla Andreeva, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Smolensk Region Clinical Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena Yakubova, PhD</last_name>
    <phone>+7 (495) 995-49-44</phone>
    <email>ey@chemrar.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalia Vostokova, PhD</last_name>
    <phone>+7 (495) 995-49-44</phone>
    <email>nv@ipharma.ru</email>
  </overall_contact_backup>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
    <mesh_term>Elsulfavirine</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

